Novogen Limited (ASX: NRT) (NASDAQ: NVGN)
has raised A$5.5million in an equity issue to substantial shareholder El
Coronado Holdings LLC at A$1.22 per share. This issue is at a...
A recently completed
Phase Ib clinical trial of a new drug to treat inflammatory bowel disease
(IBD) indicates that treatment may be possible with just a single daily
dose.
The...
NV-52 Is Part of an Emerging Class of Pharmaceutical Compounds Shown to Have a Wide Range of Beneficial Physiological EffectsAn article published in a recent edition of the peer review...
Laboratory studies presented late yesterday at the annual AACR/EORTC/NCI Molecular Targets and Cancer Therapeutics conference demonstrate that the Novogen drug candidate NV-128 induces...
New data on the Novogen oncology pipeline compound NV-128 will be presented on October 23 at the annual AACR/EORTC/NCI Molecular Targets and Cancer Therapeutics conference, to be held in...
Phase III Trial for Phenoxodiol to Recruit Nearly 500 Patients with Recurrent Ovarian Cancer at 60 Hospitals Worldwide
Researchers at the Harold C. Simmons Comprehensive Cancer Center at the...